{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:00:12Z","timestamp":1785517212006,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>High-grade serous ovarian carcinoma (HGSC) demonstrates poor prognosis with approximately 80% recurrence rates and significant chemotherapy resistance. Conventional checkpoint inhibitors show limited efficacy (10\u201315%), necessitating alternative immunotherapeutic approaches. Engineered T lymphocytes, particularly CAR-T and TCR-T cells, have emerged as promising strategies for HGSC. This literature review examines the promising role of engineered T lymphocytes in immunotherapy for HGSC. A comprehensive literature search was conducted across PubMed, Scopus, and Cochrane Library databases for peer-reviewed studies published between 2015 and 2025. Search terms included \u201cengineered T lymphocytes,\u201d \u201cCAR-T cells,\u201d \u201cTCR-T cells,\u201d \u201covarian cancer immunotherapy\u201d. CAR-T cells demonstrate promising preclinical antitumor activity in HGSC, with high-avidity T-cell clones showing robust efficacy. Engineered T lymphocytes demonstrate promising approaches across disease contexts. In high-grade serous ovarian carcinoma, Engineered T lymphocytes orchestrate tumor cell apoptosis through coordinated granzyme\/perforin and Fas\/FasL signaling, enabling rapid cytotoxic elimination of multiple tumor targets.<\/jats:p>","DOI":"10.1186\/s43046-026-00389-0","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:23:01Z","timestamp":1785162181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The promising role of engineered T lymphocytes in immunotherapy for high-grade serous ovarian carcinoma: a review of mechanisms, clinical landscape, and future strategies"],"prefix":"10.1186","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5131-6692","authenticated-orcid":false,"given":"Dwi","family":"Faradina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2268-6838","authenticated-orcid":false,"given":"Muhammad","family":"Rusda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-4091","authenticated-orcid":false,"given":"Muhammad Fidel Ganis","family":"Siregar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-6441","authenticated-orcid":false,"given":"Cut Adeya","family":"Adella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-3119","authenticated-orcid":false,"given":"Agung","family":"Putra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-7404","authenticated-orcid":false,"given":"Arya Tjipta","family":"Prananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2066-9345","authenticated-orcid":false,"given":"Dodi","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-9814","authenticated-orcid":false,"given":"Johny","family":"Marpaung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8828-861X","authenticated-orcid":false,"given":"Felix","family":"Khosasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"3","key":"389_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al \u2018Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries\u2019. CA Cancer J Clin. 2024;74(3):229\u2013263. Available at: https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"389_CR2","doi-asserted-by":"publisher","unstructured":"Li C, Wang H, Chen Y et al \u2018A Nomogram Combining MRI Multisequence Radiomics and Clinical Factors for Predicting Recurrence of High-Grade Serous Ovarian Carcinoma\u2019. J Oncol. 2022;2022, Article ID 1716268. Available at: https:\/\/doi.org\/10.1155\/2022\/1716268.","DOI":"10.1155\/2022\/1716268"},{"issue":"11","key":"389_CR3","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cam4.4600","volume":"11","author":"IP Nikas","year":"2022","unstructured":"Nikas IP, Lee C, Song MJ, Kim B, Ryu HS Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment-na\u00efve patients: A single-center study. Cancer Med. 2022;11(11):2193\u2013203. . Available at:. https:\/\/doi.org\/10.1002\/cam4.4600.","journal-title":"Cancer Med"},{"key":"389_CR4","doi-asserted-by":"publisher","unstructured":"Ghoneum A, Gonzalez D, Abdulfattah AY, Said N \u2018Metabolic Plasticity in Ovarian Cancer Stem Cells\u2019, Cancers (Basel). 2020;12(5):Article ID 1267. Available at: https:\/\/doi.org\/10.3390\/cancers12051267.","DOI":"10.3390\/cancers12051267"},{"issue":"4","key":"389_CR5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.20517\/cdr.2022.20","volume":"5","author":"AR Safa","year":"2022","unstructured":"Safa AR. \u2018Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces\u2019, Cancer Drug Resistance. 2022;5(4):850\u2013872. Available at: https:\/\/doi.org\/10.20517\/cdr.2022.20.","journal-title":"Cancer Drug Resistance"},{"key":"389_CR6","doi-asserted-by":"publisher","unstructured":"Tsuchiya H, Shiota G. \u2018Immune evasion by cancer stem cells\u2019, Regenerative Therapy. 2021;17:20\u201333. Available at: https:\/\/doi.org\/10.1016\/j.reth.2021.02.006.","DOI":"10.1016\/j.reth.2021.02.006"},{"issue":"4","key":"389_CR7","doi-asserted-by":"publisher","first-page":"e008179","DOI":"10.1136\/jitc-2023-008179","volume":"12","author":"NP Casey","year":"2024","unstructured":"Casey NP, Kleinmanns K, Forcados C, et al. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16. J Immunother Cancer. 2024;12(4):e008179. https:\/\/doi.org\/10.1136\/jitc-2023-008179.","journal-title":"J Immunother Cancer"},{"key":"389_CR8","doi-asserted-by":"publisher","first-page":"1524629","DOI":"10.3389\/fimmu.2024.1524629","volume":"15","author":"XT Chen","year":"2024","unstructured":"Chen XT, Leisegang M, Gavvovidis I, et al. Generation of effective and specific human TCRs against tumor\/testis antigen NY-ESO-1 in mice with humanized T cell recognition system. Front Immunol. 2024;15:1524629. https:\/\/doi.org\/10.3389\/fimmu.2024.1524629.","journal-title":"Front Immunol"},{"key":"389_CR9","volume-title":"statpearls [Internet]","author":"T Arora","year":"2024","unstructured":"Arora T, Mullangi S, Vadakekut ES, et al. Epithelial ovarian cancer. statpearls [Internet]. Treasure Island (FL): statpearls Publishing; 2024."},{"issue":"3","key":"389_CR10","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/ijms25031845","volume":"25","author":"V Tavares","year":"2024","unstructured":"Tavares V, Marques IS, Melo IG, Assis J, Pereira D, medeiros R. Paradigm shift: A comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci. 2024;25(3):1845. https:\/\/doi.org\/10.3390\/ijms25031845.","journal-title":"Int J Mol Sci"},{"key":"389_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, Wang X, Zhu X, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23:66. https:\/\/doi.org\/10.1186\/s12943-024-01967-3.","journal-title":"Mol Cancer"},{"key":"389_CR12","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.3390\/cancers13164178","volume":"13","author":"A Nowicki","year":"2021","unstructured":"Nowicki A, Kulus M, Wieczorkiewicz M, et al. Ovarian cancer and cancer stem cells\u2014Cellular and molecular characteristics, signaling pathways, and usefulness as a diagnostic tool in medicine and oncology. Cancers. 2021;13:4178. https:\/\/doi.org\/10.3390\/cancers13164178.","journal-title":"Cancers"},{"key":"389_CR13","unstructured":"Sauls RS, McCausland C, Taylor BN. \u2018Histology, T-Cell Lymphocyte\u2019, in: StatPearls, Treasure Island (FL): StatPearls Publishing. 2023. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535433\/."},{"issue":"1","key":"389_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2741\/4710","volume":"24","author":"H Shen","year":"2019","unstructured":"Shen H, Wu N, Nanayakkara G, et al Co-signaling receptors regulate T-cell plasticity and immune tolerance. Front Biosci (Landmark Ed). 2019;24(1):96\u2013132. Available at: 10.2741\/4682. https:\/\/doi.org\/10.2741\/4682.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"389_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1189\/jlb.3A1114-538R","volume":"97","author":"NH Overgaard","year":"2015","unstructured":"Overgaard NH, Jung J-W, Steptoe RJ, et al, \u2018CD4+\/CD8\u2009+\u2009double-positive T cells: more than just a developmental stage?\u2019. J Leukocyte Biol. 2015;97:31\u201338. Available at: https:\/\/doi.org\/10.1189\/jlb.3A1114-538R.","journal-title":"J Leukocyte Biol"},{"key":"389_CR16","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1038\/s41598-025-89270-z","volume":"15","author":"M Fu","year":"2025","unstructured":"Fu M, Zhou H, Yang J, et al \u2018Infiltration of CD8\u2009+\u2009cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma\u2019. Scientific Reps. 2025;15:4716. Available at: https:\/\/doi.org\/10.1038\/s41598-025-89270-z.","journal-title":"Scientific Reps"},{"key":"389_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0005-9","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, et al. \u2018\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges\u2019. Nat Rev Drug Discovery. 2020;19:185\u2013199. Available at: https:\/\/doi.org\/10.1038\/s41573-019-0005-9","journal-title":"Nat Rev Drug Discovery"},{"key":"389_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74\u201380. Available at:. https:\/\/doi.org\/10.1126\/science.aaa6204.","journal-title":"Science"},{"key":"389_CR19","doi-asserted-by":"publisher","first-page":"90521","DOI":"10.18632\/oncotarget.19361","volume":"8","author":"AL Xia","year":"2017","unstructured":"Xia AL, Wang XC, Lu YJ, et al. \u2018Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities\u2019, Oncotarget. 2017;8:90521\u201390531. Available at: https:\/\/doi.org\/10.18632\/oncotarget.19361.","journal-title":"Oncotarget"},{"key":"389_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-0716-0266-9_8","volume":"2111","author":"W Yang","year":"2020","unstructured":"Yang W, Chen X, Hu H. CD4\u2009+\u2009T-cell differentiation in vitro. Methods Mol Biol. 2020;2111:91\u20139. Available at:. https:\/\/doi.org\/10.1007\/978-1-0716-0266-9_8.","journal-title":"Methods Mol Biol"},{"key":"389_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.semcancer.2018.10.002","volume":"53","author":"N Ahmed","year":"2018","unstructured":"Ahmed N, Escalona R, Leung D, Chan E, Kannourakis G. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Sem Cancer Biol. 2018;53:265\u201381. . Available at:. https:\/\/doi.org\/10.1016\/j.semcancer.2018.10.002.","journal-title":"Sem Cancer Biol"},{"key":"389_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40265-017-0706-1","volume":"77","author":"KA Hay","year":"2017","unstructured":"Hay KA, Turtle CJ. \u2018Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies\u2019. Drugs. 2017:77:237\u2013245. Available at: https:\/\/doi.org\/10.1007\/s40265-017-0706-1.","journal-title":"Drugs"},{"key":"389_CR23","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","volume":"21","author":"A Miliotou","year":"2020","unstructured":"Miliotou A, Papadopoulou L, Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21:e168\u201378. Available at: 10.1016\/S1470-2045(20)30247-6. https:\/\/doi.org\/10.1016\/S1470-2045(20)30247-6.","journal-title":"Lancet Oncol"},{"key":"389_CR24","doi-asserted-by":"publisher","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM et al \u2018CRISPR-engineered T cells in patients with refractory cancer\u2019, Science. 2020;367:eaba7365. Available at: https:\/\/doi.org\/10.1126\/science.aba7365.","DOI":"10.1126\/science.aba7365"},{"issue":"8","key":"389_CR25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/diagnostics14080819","volume":"14","author":"C Cutri-French","year":"2024","unstructured":"Cutri-French C, Nasioudis D, George E, Tanyi JL. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now? Diagnostics (Basel Switzerland). 2024;14(8):819. https:\/\/doi.org\/10.3390\/diagnostics14080819.","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"389_CR26","doi-asserted-by":"publisher","first-page":"e003959","DOI":"10.1136\/jitc-2021-003959","volume":"10","author":"KG Anderson","year":"2022","unstructured":"Anderson KG, Oda SK, Bates BM, et al. Engineering adoptive T cell therapy to coopt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. J Immunother Cancer. 2022;10:e003959. https:\/\/doi.org\/10.1136\/jitc-2021-003959.","journal-title":"J Immunother Cancer"},{"key":"389_CR27","doi-asserted-by":"publisher","first-page":"1631226","DOI":"10.3389\/fimmu.2025.1631226","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Huang H, Xie R, Yang R, Wang H, Wan L. Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancer. Front Immunol. 2025;16:1631226. https:\/\/doi.org\/10.3389\/fimmu.2025.1631226.","journal-title":"Front Immunol"},{"issue":"3","key":"389_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361. Available at:. https:\/\/doi.org\/10.1038\/s41568-020-00323-z.","journal-title":"Nat Rev Cancer"},{"key":"389_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s44294-024-00010-6","volume":"2","author":"K Kleinmanns","year":"2024","unstructured":"Kleinmanns K, Bj\u00f8rge L. Enhancing precision oncology in high-grade serous carcinoma: the emerging role of antibody-based therapies. npj Womens Health. 2024;2:7. https:\/\/doi.org\/10.1038\/s44294-024-00010-6.","journal-title":"npj Womens Health"},{"issue":"9","key":"389_CR30","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1158\/2326-6066.CIR-19-0258","volume":"7","author":"KG Anderson","year":"2019","unstructured":"Anderson KG, Voillet V, Bates BM, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Cancer Immunol Res. 2019;7(9):1412\u201325. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0258.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"389_CR31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","volume":"16","author":"PP Santoiemma","year":"2015","unstructured":"Santoiemma PP, Powell DJ Jr. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015;16(6):807\u201320. https:\/\/doi.org\/10.1080\/15384047.2015.1040960.","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"389_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11912-016-0526-9","volume":"18","author":"L Mittempergher","year":"2016","unstructured":"Mittempergher L. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies. Curr Oncol Rep. 2016;18(7):44. https:\/\/doi.org\/10.1007\/s11912-016-0526-9.","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"389_CR33","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1158\/0008-5472.CAN-24-1879","volume":"85","author":"KA Lawson-Michod","year":"2025","unstructured":"Lawson-Michod KA, Marks JR, Collin LJ, Nix DA, Davidson NR, Huff CD, Yu Y, Atkinson A, Johnson CE, Salas LA, Peres LC, Greene CS, Schildkraut JM, Doherty JA. Genomic Characterization of High-Grade Serous Ovarian Carcinoma Reveals Distinct Somatic Features in Black Individuals. Cancer Res. 2025;85(9):1725\u201337. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-1879.","journal-title":"Cancer Res"},{"key":"389_CR34","doi-asserted-by":"publisher","unstructured":"Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Cancer Immunol Res. 7(9):1412\u201325. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0258.","DOI":"10.1158\/2326-6066.CIR-19-0258"},{"key":"389_CR35","doi-asserted-by":"publisher","first-page":"835762","DOI":"10.3389\/fimmu.2022.835762","volume":"13","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol. 2022;13:835762. https:\/\/doi.org\/10.3389\/fimmu.2022.835762.","journal-title":"Front Immunol"},{"key":"389_CR36","doi-asserted-by":"publisher","first-page":"115928","DOI":"10.1016\/j.biopha.2023.115928","volume":"169","author":"SI Hung","year":"2023","unstructured":"Hung SI, Chu MT, Hou MM, Lee YS, Yang CK, Chu SY, Liu FY, Hsu HC, Pao SC, Teng YC, Chen CB, Chao A, Chung WH, Chang JW, Lai CH. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer. Biomed pharmacotherapy = Biomedecine pharmacotherapie. 2023;169:115928. https:\/\/doi.org\/10.1016\/j.biopha.2023.115928.","journal-title":"Biomed pharmacotherapy = Biomedecine pharmacotherapie"},{"issue":"21","key":"389_CR37","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1158\/1078-0432.CCR-18-0142","volume":"24","author":"T Matsuda","year":"2018","unstructured":"Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin cancer research: official J Am Association Cancer Res. 2018;24(21):5357\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0142.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"389_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s40425-019-0629-6","volume":"7","author":"S Liu","year":"2019","unstructured":"Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, et al. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019;7:156. https:\/\/doi.org\/10.1186\/s40425-019-0629-6.","journal-title":"J Immunother Cancer"},{"key":"389_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, et al. Neoantigens: promising targets for cancer therapy. Sig Transduct Target Ther. 2023;8:9. https:\/\/doi.org\/10.1038\/s41392-022-01270-x.","journal-title":"Sig Transduct Target Ther"},{"issue":"6","key":"389_CR40","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.hoc.2018.07.011","volume":"32","author":"T Chodon","year":"2018","unstructured":"Chodon T, Lugade AA, Battaglia S, Odunsi K. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. Hematol Oncol Clin N Am. 2018;32(6):1025\u201339. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.011.","journal-title":"Hematol Oncol Clin N Am"},{"key":"389_CR41","doi-asserted-by":"publisher","first-page":"e006822","DOI":"10.1136\/jitc-2023-006822","volume":"12","author":"R Amaria","year":"2024","unstructured":"Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, et al. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024;12:e006822. https:\/\/doi.org\/10.1136\/jitc-2023-006822.","journal-title":"J Immunother Cancer"},{"key":"389_CR42","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1038\/s41467-025-59818-8","volume":"16","author":"T Kimman","year":"2025","unstructured":"Kimman T, Cuenca M, Tieland RG, et al. Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation. Nat Commun. 2025;16:4638. https:\/\/doi.org\/10.1038\/s41467-025-59818-8.","journal-title":"Nat Commun"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00389-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:06:29Z","timestamp":1785513989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00389-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00389-0","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"51"}}